Solid Dosage Contract Manufacturing Market Size, Share, Competitive Landscape and Trend Analysis Report by API Manufacturing and by Solid Dosage Manufacturing : Opportunity Analysis and Industry Forecast, 2023-2032

Every data presented in the reports published by Allied Market Research is captured through primary interviews with top officials from leading organizations of the concerned domain. Our secondary data procurement methodology involves deep online and offline research and discussion with expert professionals and analysts in the industry. Moreover, the global Solid dosage contract manufacturing market report takes in the facts & figures of market growth & development, detailed study of the value chain, prevalent case studies, and profiles of the major players along with other qualitative segments. The top market players are thoroughly examined based on their revenue size. The report outlines how these players have taken recourse to several strategies including expansion, partnership, joint undertakings, and others to highlight their flair in the industry.

Key players identified in this report are Novartis International AG, Aurobindo Pharma Ltd., Teva Pharmaceutical Industries Ltd., Baxter International Inc., Mylan N.V., Sun Pharmaceutical Industries Ltd., Merck KGaA, Eli Lilly and Company, Recipharm AB, Glenmark Pharmaceuticals Ltd.

Key Takeaways

• Qualitative and quantitative analysis of the global Solid dosage contract manufacturing market based on by api manufacturing, by solid dosage manufacturing

• Current growth trends and market opportunities

• Regional and country level forecast

• Company profiles of the top market players

• Detailed study of the drivers, restraints, and opportunities

• Financial assessment of the portfolios of the key market players

Scope of the Report

The global Solid dosage contract manufacturing market report by AMR provides analysis of the current niches in the sector. The extensive research study offers significant information along with focusing on the drivers, restraints, and opportunities of the market. It also aims to role out wide-ranging information on the latest market trends and approaches.

Target Audience

• Suppliers

• Governments Bodies

• Distributors

• C-level Executives

• Venture Capitalists

• Universities

In this study, the years considered to estimate the market size of Solid dosage contract manufacturing market are as follows:

• Base Year: 2022

• Forecast Year: 2024

• Unit: Value (USD Million/Billion)

  Solid Dosage Contract Manufacturing Market Report Highlights

Aspects	Details
By API Manufacturing	Low Potency Drugs High Potency Drugs
By Solid Dosage Manufacturing	Tablets Capsules Sachets
By Region	North America  (U.S., Canada, Mexico) Europe  (France, Germany, Italy, Spain, UK, Russia, Rest of Europe) Asia-Pacific  (China, Japan, India, South Korea, Australia, Thailand, Malaysia, Indonesia, Rest of Asia-Pacific) LAMEA  (Brazil, South Africa, Saudi Arabia, UAE, Argentina, Rest of LAMEA)
Key Market Players	Sun Pharmaceutical Industries Ltd., Eli Lilly and Company, Aurobindo Pharma Ltd., Merck KGaA, Novartis International AG, Teva Pharmaceutical Industries Ltd., Mylan N.V., Recipharm AB, Baxter International Inc., Glenmark Pharmaceuticals Ltd.

^*Terms and Conditions Apply